Results for tag: "Chronic Myelomonocytic Leukemia Drug"

Chronic Myelomonocytic Leukemia (CMML) is a rare form of leukemia that affects the bone marrow and blood. It is characterized by an increase in monocytes, a type of white blood cell, and anemia. Treatment for CMML includes chemotherapy, stem cell transplantation, and targeted therapies. The CMML drug market is a subset of the larger leukemia drug market. It is composed of drugs used to treat CMML, such as azacitidine, decitabine, and midostaurin. These drugs are used to reduce the number of monocytes in the blood, reduce anemia, and reduce the risk of complications. The companies in the CMML drug market include Novartis, Celgene, Pfizer, and AstraZeneca. These companies produce and market drugs used to treat CMML. They also conduct research and development to develop new treatments for the disease. Show Less Read more